NCT lookup

Pull any trial record directly from ClinicalTrials.gov.

Quality of Life Study in Participants With IPF Under Pirfenidone Treatment

CompletedN/A

Sponsor: Hoffmann-La Roche

Conditions: Idiopathic Pulmonary Fibrosis

Interventions: Pirfenidone

Countries: Greece

This multicenter, post-marketing, observational study will evaluate quality of life in participants with Idiopathic Pulmonary Fibrosis (IPF) under treatment with pirfenidone (Esbriet).

Eligibility overview

Sex: ALL

Age: 18 Years to —

Healthy volunteers: No

Study type: OBSERVATIONAL

Eligibility criteria

Inclusion Criteria:

* Adult participants for whom pirfenidone has already been prescribed for IPF no more than 4 weeks prior to enrollment, according to their physicians' clinical decision and the terms in the SmPC

Exclusion Criteria:

* Participants who are participating in an interventional study or have received any investigational agent in the past 4 weeks

Locations (7)

Athens, Greece
Chaïdári, Greece
Heraklio, Greece
Ioannina, Greece
Larissa, Greece
Thessaloniki, Greece
Thessaloniki, Greece